Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $16.69, for a total value of $917,950.00. Following the sale, the chief executive officer now directly owns 276,017 shares in the company, valued at $4,606,723.73. This represents a 16.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.93, for a total transaction of $876,150.00.
• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA traded down $0.54 during trading hours on Friday, hitting $15.75. 1,555,582 shares of the company traded hands, compared to its average volume of 524,057. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -10.29 and a beta of 1.54. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The firm has a 50-day moving average of $16.46 and a 200 day moving average of $16.36. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $31,000. GAMMA Investing LLC grew its stake in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC grew its stake in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $171,000. Institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CNTA shares. Morgan Stanley restated an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Finally, TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.